miRNA-181a and miRNA-128 expression levels as a predictive marker for response in treating Acute Lymphoblastic Leukemia
Abstract
Background: The genesis of Acute Lymphoblastic Leukemia (ALL) has been established to involve the workings of certain microRNAs (miRNAs), such as miR-181a and miR-128. As such, science research has been exploring their potential as biological markers for various therapeutic uses, such as disease detection, relapse likelihood prediction, and monitoring of patient treatment response. Moreover, identifying additional miRNA biomarkers can also enable scientists to develop new treatment approaches in their entirety.
Methods: This study examined 100 participants, including 70 ALL patients—i.e., 40 in remission, 20 who relapsed, and 10 who were resistant—and 30 healthy controls. Researchers employed RT-qPCR to identify and quantify expressions of miR-181a and miR-128 in blood samples and statistically compared expressions in all these groups.
Results: The expression analysis revealed significant differences between the study groups for both miRNA-181a and miRNA-128 (p < 0.001). The highest peak level of expression was noted in the relapse group in comparison to the response, resistant, and control participants. Furthermore, in relapse, response, and resistant groups, there was significantly elevated expression (p < 0.05), and control levels were lowest of all (p < 0.05).
Conclusion: Quantitation of expression levels of miR-181a and miR-128 holds great promise in predicting treatment response in ALL patients. More importantly, miR-181a shows promise as a specific and sensitive biomarker in predicting resistance and relapse in adult ALL patients.
Keywords: miRNA-181a, Biomarkers, Acute Lymphoblastic Leukemia (ALL), miRNA-128, Treatment Response, Relapse Prediction
Full Text:
PDFReferences
Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer Journal, (2017); 7(6): e577-e577.
Becerra EB, García-Alcocer G. (2021) MicroRNAs and Their Role in Acute Lymphoblastic Leukemia. Acute Leukemias. London, United Kingdom: IntechOpen. pp. 109.
Lazuwardi RA, Andarsini MR, Hernaningsih Y. Clinical and laboratory effects of exchange transfusion in pediatric acute lymphoblastic leukemia with hyperleukocytosis. Paediatrica Indonesiana, (2023); 63(6): 464-471.
Al-Hashimi MM. Incidence of childhood leukemia in Iraq, 2000-2019. Asian Pacific Journal of Cancer Prevention, (2021); 22(11): 3663-3670.
Mjali A, Matti BF, Kareem Y, Hasan DA, Alharganee A, et al. Hyper-CVAD protocol versus UKALL protocol and the minimal residual disease status in adult acute lymphoblastic leukemia patients. International Journal of Medical Research & Health Sciences, (2020); 9(10): 1-7.
Abou Dalle I, Jabbour E, Short NJ. Evaluation and management of measurable residual disease in acute lymphoblastic leukemia. Therapeutic Advances in Hematology, (2020); 11(2020): 1-13.
El Desoky A, Badrawy H, Abd El Razik DI, Riad KF, Abdelhamid ON, et al. Predictive value of miRNA-181a in pediatric acute lymphoblastic leukemia. Journal of Cancer Therapy, (2020); 11(11): 673-682.
Luan C, Yang Z, Chen B. The functional role of microRNA in acute lymphoblastic leukemia: relevance for diagnosis, differential diagnosis, prognosis, and therapy. OncoTargets and Therapy, (2015); 8(2015): 2903-2914.
Neilson JR, Zheng GX, Burge CB, Sharp PA. Dynamic regulation of miRNA expression in ordered stages of cellular development. Genes & Development, (2007); 21(5): 578-589.
Dawidowska M, Jaksik R, Drobna M, Szarzyńska-Zawadzka B, Kosmalska M, et al. Comprehensive investigation of miRNome identifies novel candidate miRNA-mRNA interactions implicated in T-cell acute lymphoblastic leukemia. Neoplasia, (2019); 21(3): 294-310.
Duyu M, Durmaz B, Gunduz C, Vergin C, Yilmaz Karapinar D, et al. Prospective evaluation of whole genome microRNA expression profiling in childhood acute lymphoblastic leukemia. BioMed Research International, (2014); 2014(1): 967585.
Rzepiel A, Kutszegi N, Gézsi A, Sági JC, Egyed B, et al. Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia. Journal of Translational Medicine, (2019); 17(2019): 1-16.
Shafik RE, Abd El Wahab N, Senoun SA, Ebeid E, El Taweel MA. Expression of micro-RNA 128 and let-7b in pediatric acute lymphoblastic leukemia cases. Asian Pacific Journal of Cancer Prevention, (2018); 19(8): 2263-2267.
Akpinar F, Polat A, Balci YI, Akça H, Şenol H, et al. Microrna expression profiles and changes with treatment on childhood leukemias. UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi, (2020); 30(2): 72-80.
Grobbelaar C, Ford AM. The role of MicroRNA in paediatric acute lymphoblastic leukaemia: challenges for diagnosis and therapy. Journal of Oncology, (2019); 2019(1): 8941471.
Nemes K, Csóka M, Nagy N, Márk Á, Váradi Z, et al. Expression of certain leukemia/lymphoma related microRNAs and its correlation with prognosis in childhood acute lymphoblastic leukemia. Pathology & Oncology Research, (2015); 21(2015): 597-604.
Vardhana S, Younes A. The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. Haematologica, (2016); 101(7): 794-802.
Han BW, Feng DD, Li ZG, Luo XQ, Zhang H, et al. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Human Molecular Genetics, (2011); 20(24): 4903-4915.
Yamada N, Noguchi S, Kumazaki M, Shinohara H, Miki K, et al. Epigenetic regulation of microRNA-128a expression contributes to the apoptosis-resistance of human T-cell leukaemia jurkat cells by modulating expression of fas-associated protein with death domain (FADD). Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, (2014); 1843(3): 590-602.
Mi S, Lu J, Sun M, Li Z, Zhang H, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proceedings of the National Academy of Sciences, (2007); 104(50): 19971-19976.
Palumbo T, Faucz FR, Azevedo M, Xekouki P, Iliopoulos D, et al. Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN–AKT pathway. Oncogene, (2013); 32(13): 1651-1659.
Martinez N, Almaraz C, Vaqué J, Varela I, Derdak S, et al. Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. Leukemia, (2014); 28(6): 1334-1340.
Rainer J, Ploner C, Jesacher S, Ploner A, Eduardoff M, et al. Glucocorticoid-regulated microRNAs and mirtrons in acute lymphoblastic leukemia. Leukemia, (2009); 23(4): 746-752.
Wallaert A, Van Loocke W, Hernandez L, Taghon T, Speleman F, et al. Comprehensive miRNA expression profiling in human T-cell acute lymphoblastic leukemia by small RNA-sequencing. Scientific Reports, (2017); 7(1): 7901.
Gutierrez-Camino A, Lopez-Lopez E, Martin-Guerrero I, Piñan MA, Garcia-Miguel P, et al. Noncoding RNA–related polymorphisms in pediatric acute lymphoblastic leukemia susceptibility. Pediatric Research, (2014); 75(6): 767-773.
Nabhan M, Louka ML, Khairy E, Tash F, Ali-Labib R, et al. MicroRNA-181a and its target Smad 7 as potential biomarkers for tracking child acute lymphoblastic leukemia. Gene, (2017); 628(2017): 253-258.
Anelli L, Zagaria A, Specchia G, Musto P, Albano F. Dysregulation of miRNA in leukemia: exploiting miRNA expression profiles as biomarkers. International Journal of Molecular Sciences, (2021); 22(13): 7156.
Kibria G, Hatakeyama H, Harashima H. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Archives of Pharmacal Research, (2014); 37(2014): 4-15.
Haque S, Vaiselbuh SR. Silencing of exosomal miR-181a reverses pediatric acute lymphocytic leukemia cell proliferation. Pharmaceuticals, (2020); 13(9): 241.
Yin JAL, O'Brien MA, Hills RK, Daly SB, Wheatley K, et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood, (2012); 120(14): 2826-2835.
DOI: http://dx.doi.org/10.62940/als.v12i3.2334
Refbacks
- There are currently no refbacks.